Huma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder Cancer Patients

London (ots/PRNewswire) - Huma Therapeutics ("Huma"), a leader in global digital
health innovation, together with Merck KGaA, Darmstadt, Germany, a leading
science and technology company, today announced the launch of their innovative
bladder cancer treatment companion app in the United Kingdom. This collaboration
underscores Merck KGaA, Darmstadt, Germany and Huma's joint commitment to
advancing patient-directed care and empowering patients and caregivers
throughout their cancer care pathway.

The UK launch marks a significant milestone in the partnership between Huma and
Merck KGaA, Darmstadt, Germany, announced in November 2023. Additional markets
are planned for launch in the coming year, and may support delivery of care for
a range of cancers.

Enabling Better Care Experiences for Cancer Patients

The bladder cancer treatment companion app developed by Huma and Merck KGaA,
Darmstadt, Germany, is designed to support patients and caregivers in navigating
the complexities of bladder cancer treatment by providing a reliable source of
information and support throughout the treatment journey. Built in collaboration
with healthcare professionals and leading patient organisations, the app aims to
provide patients with:

- Improved understanding of their treatment
- Better conversations with their care team
- Self-tracking of their health state
- Raising awareness of available holistic care services
- Encouraging connection with personal support network
- Expectation management and motivation through content

UK-based patient organisations and specialist cancer care centres were involved
in and piloting the bladder cancer treatment journey app in advance of the
launch.

Alex Filicevas, Executive Director at the World Bladder Cancer Patient
Coalition, emphasised the importance of the app in supporting patients and
caregivers through a complex treatment journey: "It was a privilege to work
alongside patients with bladder cancer and their caregivers, helping to shape a
new digital resource for patients with bladder cancer to guide them through the
complex path of treatment. This initiative underscores our joint dedication to
fostering patient empowerment, shared decision-making and community within
healthcare delivery."

Joachim Chan, a consultant clinical oncologist at the Clatterbridge Cancer
Centre in Liverpool, noted the importance of patients being well-informed:
"Although there is a wealth of knowledge available to patients through various
websites, patients may understandably want a reliable source of information
through a single portal. Merck KGaA, Darmstadt, Germany has collaborated with
various stakeholders to create an app to this end. This app will give clear